1. Chen NX, Srinivasan S, O’Neill K, Nickolas TL. Effect of advanced glycation end-products (AGE) lowering drug ALT-711 on biochemical, vascular, and bone parameters in a rat model of CKD-MBD. J Bone Miner Res. 2020;35(3):608–17.
2. Cianciolo G, La Manna G, Capelli I, Gasperoni L, Galassi A, Ciceri P, et al. The role of activin: the other side of chronic kidney disease-mineral bone disorder? Nephrol Dial Transplant. 2020.
3. Chen NX, Moe SM. Pathophysiology of vascular calcification. Curr Osteoporos Rep. 2015;13(6):372–80.
4. Viegas C, Araújo N, Marreiros C, Simes D. The interplay between mineral metabolism, vascular calcification and inflammation in chronic kidney disease (CKD): challenging old concepts with new facts. Aging. 2019;11(12):4274–99.
5. Jegatheesan D, Cho Y, Johnson DW. Clinical studies of interventions to mitigate cardiovascular risk in peritoneal dialysis patients. Semin Nephrol. 2018;38(3):277–90.